Inspra® reduces risk of recurrent heart failure hospitalisation Pharmacy Europe Results of this sub-analysis showed that despite fewer deaths in the eplerenone group compared with placebo, there were fewer recurrent hospitalisations. Heart failure hospitalisation rates in the eplerenone and placebo groups were 11.1 and 17.9 per ... |
